Log in
Language:

MERAL Myanmar Education Research and Learning Portal

  • Top
  • Universities
  • Ranking
To
lat lon distance
To

Field does not validate



Index Link

Index Tree

Please input email address.

WEKO

One fine body…

WEKO

One fine body…

Item

{"_buckets": {"deposit": "29723fcb-c66e-4444-9396-221611e76cee"}, "_deposit": {"created_by": 100, "id": "7886", "owner": "100", "owners": [100], "owners_ext": {"displayname": "hlahlawin", "username": "hlahlawin"}, "pid": {"revision_id": 0, "type": "depid", "value": "7886"}, "status": "published"}, "_oai": {"id": "oai:meral.edu.mm:recid/00007886", "sets": ["user-um2"]}, "communities": ["um2"], "item_1583103067471": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "The clinical utility of the urine-basedlateral flow lipoarabinomannan assayin HIV-infected adults in Myanmar:an observational study", "subitem_1551255648112": "en"}]}, "item_1583103085720": {"attribute_name": "Description", "attribute_value_mlt": [{"interim": "Background:The use of the point-of-care lateral flow lipoarabinomannan (LF-LAM) test may expedite tuberculosis(TB) diagnosis in HIV-positive patients. However, the test’s clinical utility is poorly defined outside sub-Saharan Africa.Methods:The study enrolled consecutive HIV-positive adults at a tertiary referral hospital in Yangon, Myanmar. Onenrolment, patients had a LF-LAM test performed according to the manufacturer’s instructions. Clinicians managingthe patients were unaware of the LF-LAM result, which was correlated with the patient’s clinical course over theensuing 6 months.Results:The study enrolled 54 inpatients and 463 outpatients between July 1 and December 31, 2015. On enrolment,the patients’median (interquartile range) CD4 T-cell count was 270 (128–443) cells/mm3. The baseline LF-LAM testwas positive in 201/517 (39%). TB was confirmed microbiologically during follow-up in 54/517 (10%), with rifampicinresistance present in 8/54 (15%). In the study’s resource-limited setting, extrapulmonary testing for TB was not possible,but after 6 months, 97/201 (48%) with a positive LF-LAM test on enrolment had neither died, required hospitalisation,received a TB diagnosis or received empirical anti-TB therapy, suggesting a high rate of false-positive results.Of the 97 false-positive tests, 89 (92%) were grade 1 positive, suggesting poor test specificity using this cut-off. Only21/517 (4%) patients were inpatients with TB symptoms and a CD4 T-cell count of \u003c 100 cells/mm3. Five (24%) of these21 died, three of whom had a positive LF-LAM test on enrolment. However, all three received anti-TB therapy beforedeath—two after diagnosis with Xpert MTB/RIF testing, while the other received empirical treatment. It is unlikely thatknowledge of the baseline LF-LAM result would have averted any of the study’s other 11 deaths; eight had a negativetest, and of the three patients with a positive test, two received anti-TB therapy before death, while one died fromlaboratory-confirmed cryptococcal meningitis. The test was no better than a simple, clinical history excluding TB duringfollow-up (negative predictive value (95% confidence interval): 94% (91–97) vs. 94% (91–96)).\nConclusions:The LF-LAM test had limited clinical utility in the management of HIV-positive patients in this Asianreferral hospital setting."}]}, "item_1583103108160": {"attribute_name": "Keywords", "attribute_value_mlt": [{"interim": "Human immunodeficiency virus"}, {"interim": "Tuberculosis"}, {"interim": "Diagnostic test"}, {"interim": "Clinical management"}, {"interim": "Myanmar"}]}, "item_1583103120197": {"attribute_name": "Files", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2021-01-28"}], "displaytype": "preview", "download_preview_message": "", "file_order": 0, "filename": "The_clinical_utility_of_the_urine-based_lateral_fl.pdf", "filesize": [{"value": "1008 KB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_0", "mimetype": "application/pdf", "size": 1008000.0, "url": {"url": "https://meral.edu.mm/record/7886/files/The_clinical_utility_of_the_urine-based_lateral_fl.pdf"}, "version_id": "ba6012b0-69de-465f-9374-7d3beec14578"}]}, "item_1583103131163": {"attribute_name": "Journal articles", "attribute_value_mlt": [{"subitem_issue": "15", "subitem_journal_title": "BMC Medicine", "subitem_pages": "1-11"}]}, "item_1583105942107": {"attribute_name": "Authors", "attribute_value_mlt": [{"subitem_authors": [{"subitem_authors_fullname": "Swe Swe Thit"}, {"subitem_authors_fullname": "Ne Myo Aung"}, {"subitem_authors_fullname": "Zaw Win Htet"}, {"subitem_authors_fullname": "Boyd, Mark A."}, {"subitem_authors_fullname": "Htin Aung Saw"}, {"subitem_authors_fullname": "Anstey, Nicholas M."}, {"subitem_authors_fullname": "Tint Tint Kyi"}, {"subitem_authors_fullname": "Cooper,  David A."}, {"subitem_authors_fullname": "Mar Mar Kyi"}, {"subitem_authors_fullname": "Hanson, Josh"}]}]}, "item_1583108359239": {"attribute_name": "Upload type", "attribute_value_mlt": [{"interim": "Publication"}]}, "item_1583108428133": {"attribute_name": "Publication type", "attribute_value_mlt": [{"interim": "Journal article"}]}, "item_1583159729339": {"attribute_name": "Publication date", "attribute_value": "2017-02-28"}, "item_1583159847033": {"attribute_name": "Identifier", "attribute_value": "DOI 10.1186/s12916-017-0888-3"}, "item_title": "The clinical utility of the urine-basedlateral flow lipoarabinomannan assayin HIV-infected adults in Myanmar:an observational study", "item_type_id": "21", "owner": "100", "path": ["1608053322572"], "permalink_uri": "http://hdl.handle.net/20.500.12678/0000007886", "pubdate": {"attribute_name": "Deposited date", "attribute_value": "2021-01-28"}, "publish_date": "2021-01-28", "publish_status": "0", "recid": "7886", "relation": {}, "relation_version_is_last": true, "title": ["The clinical utility of the urine-basedlateral flow lipoarabinomannan assayin HIV-infected adults in Myanmar:an observational study"], "weko_shared_id": -1}
  1. University of Medicine 2
  2. Department of Medicine

The clinical utility of the urine-basedlateral flow lipoarabinomannan assayin HIV-infected adults in Myanmar:an observational study

http://hdl.handle.net/20.500.12678/0000007886
http://hdl.handle.net/20.500.12678/0000007886
b8603b9d-eac7-4543-9dfd-3970d4fc7ca9
29723fcb-c66e-4444-9396-221611e76cee
None
Preview
Name / File License Actions
The_clinical_utility_of_the_urine-based_lateral_fl.pdf The_clinical_utility_of_the_urine-based_lateral_fl.pdf (1008 KB)
license.icon
Publication type
Journal article
Upload type
Publication
Title
Title The clinical utility of the urine-basedlateral flow lipoarabinomannan assayin HIV-infected adults in Myanmar:an observational study
Language en
Publication date 2017-02-28
Authors
Swe Swe Thit
Ne Myo Aung
Zaw Win Htet
Boyd, Mark A.
Htin Aung Saw
Anstey, Nicholas M.
Tint Tint Kyi
Cooper, David A.
Mar Mar Kyi
Hanson, Josh
Description
Background:The use of the point-of-care lateral flow lipoarabinomannan (LF-LAM) test may expedite tuberculosis(TB) diagnosis in HIV-positive patients. However, the test’s clinical utility is poorly defined outside sub-Saharan Africa.Methods:The study enrolled consecutive HIV-positive adults at a tertiary referral hospital in Yangon, Myanmar. Onenrolment, patients had a LF-LAM test performed according to the manufacturer’s instructions. Clinicians managingthe patients were unaware of the LF-LAM result, which was correlated with the patient’s clinical course over theensuing 6 months.Results:The study enrolled 54 inpatients and 463 outpatients between July 1 and December 31, 2015. On enrolment,the patients’median (interquartile range) CD4 T-cell count was 270 (128–443) cells/mm3. The baseline LF-LAM testwas positive in 201/517 (39%). TB was confirmed microbiologically during follow-up in 54/517 (10%), with rifampicinresistance present in 8/54 (15%). In the study’s resource-limited setting, extrapulmonary testing for TB was not possible,but after 6 months, 97/201 (48%) with a positive LF-LAM test on enrolment had neither died, required hospitalisation,received a TB diagnosis or received empirical anti-TB therapy, suggesting a high rate of false-positive results.Of the 97 false-positive tests, 89 (92%) were grade 1 positive, suggesting poor test specificity using this cut-off. Only21/517 (4%) patients were inpatients with TB symptoms and a CD4 T-cell count of < 100 cells/mm3. Five (24%) of these21 died, three of whom had a positive LF-LAM test on enrolment. However, all three received anti-TB therapy beforedeath—two after diagnosis with Xpert MTB/RIF testing, while the other received empirical treatment. It is unlikely thatknowledge of the baseline LF-LAM result would have averted any of the study’s other 11 deaths; eight had a negativetest, and of the three patients with a positive test, two received anti-TB therapy before death, while one died fromlaboratory-confirmed cryptococcal meningitis. The test was no better than a simple, clinical history excluding TB duringfollow-up (negative predictive value (95% confidence interval): 94% (91–97) vs. 94% (91–96)).
Conclusions:The LF-LAM test had limited clinical utility in the management of HIV-positive patients in this Asianreferral hospital setting.
Keywords
Human immunodeficiency virus, Tuberculosis, Diagnostic test, Clinical management, Myanmar
Identifier DOI 10.1186/s12916-017-0888-3
Journal articles
15
BMC Medicine
1-11
Back
0
0
views
downloads
See details
Views Downloads

Versions

Ver.1 2021-01-28 09:29:07.985482
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Export

OAI-PMH
  • OAI-PMH DublinCore
Other Formats
  • JSON

Confirm


Back to MERAL


Back to MERAL